Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Increased mRNA translation delays tumor initiation and exposes a therapeutic vulnerability in lung cancer

ABSTRACT: Although protein synthesis inhibitors are being evaluated as anti-cancer agents, the dynamics of mRNA translation in early tumorigenesis are still poorly understood. We report that deletion of the mRNA-translation repressor, eIF4A2 in early KRAS-driven lung adenocarcinoma leads to a dysregulated protein synthesis landscape characterised by a strongly upregulated secretome, enlarged secretory compartments, increased oxidative metabolism and acquisition of senescence-like characteristics. Paradoxically, this overdriven protein synthesis landscape delays tumorigenesis and leads to appearance of clusters of non-proliferative, p21-positive KRAS-expressing cells in the lung. Administration of rapamycin to reduce mRNA translation, suppresses senescence and restores tumorigenesis following eIF4A2 deletion. Importantly, some eIF4A2 deleted cells overcome senescence to form tumors that growth aggressively. Analysis of these eIF4A2-deleted tumors through a combination of multiplex imaging and spatial transcriptomics pointed to a rewiring of KRAS downstream pathways through enhanced MAP-kinase and reduced PI3K signalling. Consequently, these tumors may be eradicated by administration of a MEK inhibitor, in contrast to eIF4A2 positive lesions. Thus, dysregulated mRNA translation exposes a potential therapeutic vulnerability in KRAS-driven lung adenocarcinoma by forcing cancer cells to rely on MEK signalling.

ORGANISM(S): Mus musculus

PROVIDER: GSE327213 | GEO | 2026/07/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

eIF4A2 targets developmental potency and histone H3.3 transcripts for translational control of stem cell pluripotency

Project description:Translational control has emerged as a fundamental regulatory layer of proteome complexity that governs cellular identity and functions. As initiation is the rate-limiting step of translation, we carried out an RNAi screen for key translation initiation factors required to maintain embryonic stem cell (ESC) identity. We identified eIF4A2 and defined its mechanistic action through Rps26-independent and -dependent ribosomes in translation initiation activation of mRNAs encoding pluripotency factors and the histone variant H3.3 with demonstrated roles in maintaining stem cell pluripotency. eIF4A2 also mediates translation initiation activation of Ddx6, which acts together with eIF4A2 to restrict the totipotent 2-cell transcription program in ESCs through Zscan4 mRNA degradation and translation repression. Accordingly, knockdown of eIF4A2 disrupts ESC proteome causing the loss of ESC identity. Collectively, we establish a translational paradigm of the protein synthesis of pluripotency transcription factors and epigenetic regulators imposed on their established roles in controlling pluripotency.

2024-12-20 | GSE192843 | GEO

eIF4A2 targets developmental potency and histone H3.3 transcripts for translational control of embryonic and cancer stemness [Ribo-seq]

Project description:Stemness is a defining feature in embryonic and cancer stem cells. How stemness is regulated at the mRNA translational initiation remains undefined. We carried out an RNAi screen for key translation initiation factors that maintain the stemness in mouse embryonic stem cells (ESCs). We identified eIF4A2 and defined its mechanistic action through Rps26-depleted and -containing ribosomes in translational initiation activation of mRNAs encoding pluripotency factors and H3.3 for embryonic and extraembryonic lineage repression, respectively. eIF4A2 also mediates translation initiation activation of Ddx6, which acts together with eIF4A2 to restrict the totipotent 2-cell (2C) transcription program in ESCs through Zscan4 mRNA degradation and translation repression. Knockdown of eIF4A2 disrupts ESC proteome causing the loss of stemness in ESCs as well as in human glioblastomas where eIF4A2 is highly enriched. Collectively, our study establishes an eIF4A2-mediated translation initiation control of stemness and provides insight into cancer therapeutics targeting the translation initiation machinery.

2022-04-20 | GSE150676 | GEO

eIF4A2 targets developmental potency and histone H3.3 transcripts for translational control of embryonic and cancer stemness [RNA-seq]

2022-04-20 | GSE150673 | GEO

eIF4A2 targets developmental potency and histone H3.3 transcripts for translational control of embryonic and cancer stemness [eCLIP-seq]

2022-04-20 | GSE150680 | GEO

Interactome of Eif4a2 in mouse embryonic stem cells

Project description:Cell fate transitions depend on balanced rewiring of transcription and translation programmes to enable ordered developmental progression. We identified a feedback loop between nonsense-mediated mRNA decay (NMD) and translation initiation, in which NMD controls the translation initiation factor Eif4a2 and its premature termination codon encoding isoform (Eif4a2-PTC). This leads to translation of a specific truncated protein, which elicits increased translation rates and is causative for significant delays in mouse embryonic stem cell differentiation. Using immunoprecipitation coupled with mass spectrometry, we identified the interactome of full length Eif4a2 (Eif4a2-iso1) and Eif4a2-PTC. We find that Eif4a2-iso1 is mainly involved in translation initiation, while unstable Eif4a2-PTC shows little interaction with translation initiation factors. Both isoforms can bind to mRNA, as indicated by the interaction with mRNA binding protein, such as NMD factors and Ago2. Finally, Eif4a2-iso1 and Eif4a2-PTC interact with key pluripotency factors, providing a potential explanation for how Eif4a2 controls ESC differentiation.

2022-03-09 | PXD019588 | Pride

De novo lipogenesis represents a therapeutic target in Kras mutant NSCLC

Project description:We examine the potential of Kras as a metabolic target in lung cancer using the KrasLSL-G12D lung cancer model. We demonstrate that mutant Kras drives a lipogenic gene expression program, and that fatty acid synthesis is important in Kras-induced tumorigenesis. Compare gene expression changes between mutant Kras (G12D) driven lung tumors and normal lung samples to identify pathways selectively altered in lung tumors.

2018-04-27 | GSE113717 | GEO

Oncogenic KRAS promotes pancreatic ductal adenocarcinoma (PDAC) through post-transcriptionally regulated KRAS-induced granules (KGs) [miRNA-seq]

Project description:Over 90% of pancreatic ductal adenocarcinoma (PDAC) tumors harbor mutations in KRAS which promote many hallmark characteristics of cancer. How a single driver mutation causes the malignant properties observed in PDAC is poorly understood. We discovered that oncogenic KRAS suppresses miRNA biogenesis and function, thus increasing the stability and translation efficiency of miRNA targets. Defective miRNA function causes an accumulation of mRNA, and drives the localization of components of the mRNA degradation machinery into novel post-transcriptional condensates termed KRAS-induced granules (KGs). Mechanistically, we find that KG formation depends on the phosphorylation of Argonaute2 at tyrosine393 and requires EGFR, but not MEK or PI3K signaling. Using in vivo and in vitro models, we find that genetic ablation of KGs leads to decreased proliferation and migration, delayed tumorigenesis, and reduced tumor angiogenesis and innervation. Our findings reveal an essential and therapeutically targetable role for altered post-transcriptional regulation in PDAC tumorigenesis.

2026-08-17 | GSE239309 | GEO

Oncogenic KRAS promotes pancreatic ductal adenocarcinoma (PDAC) through post-transcriptionally regulated KRAS-induced granules (KGs) [RNA-seq]

2026-08-17 | GSE239297 | GEO

Oncogenic KRAS promotes pancreatic ductal adenocarcinoma (PDAC) through post-transcriptionally regulated KRAS-induced granules (KGs) [SLAM-seq]

2026-08-17 | GSE281227 | GEO

Methylated eEF1A Selectively Decodes mRNA to Shape Cancer Proteomes

Project description:Differences in mRNA decoding efficiency influence protein synthesis. However, whether the translation elongation machinery harbors an intrinsic mechanism that selectively decodes codons—and how this shapes proteomes in homeostasis and disease—remains unknown. Here we find that METTL13-catalyzed dimethylation of the elongation factor eEF1A at lysine 55 (eEF1AK55me2) enhances decoding of select codons, thereby preferentially increasing synthesis of pro-oncogenic proteins, including KRAS, to promote tumorigenesis and targeted therapy resistance. Proteomic profiling and single-molecule imaging reveal that eEF1AK55me2 increases decoding efficiency, particularly for underrepresented codons with weak wobble-position basepairing. In cancer cells, METTL13 knockdown reduced synthesis of oncogenic proteins encoded by genes enriched in eEF1AK55me2-dependent codons—including KRAS—an effect reversed by synonymous recoding with eEF1AK55me2-independent codons. KRAS recoding also attenuated anti-neoplastic effects of METTL13 depletion. Loss of METTL13 inhibited growth of KRASG12Cinhibitor(sotorasib)-resistant syngeneic and patient-derived lung adenocarcinoma (LUAD) xenografts. Further, METTL13 ablation in relapsed autochthonous KRASG12C-driven LUAD tumors mitigated sotorasib resistance, significantly extending survival in vivo. Finally, in clinical trial patients treated with the KRASG12C-inhibitor adagrasib, inferred METTL13 activity was associated with inferior clinical response. These findings identify an eEF1AK55me2-mediated mRNA decoding mechanism that promotes selective oncogenic protein synthesis and suggest that METTL13 targeting may counteract tumor resistance to KRAS inhibitors.

2026-08-14 | GSE335287 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data